The Big Picture
Federal and state policy moves dominated cannabis headlines on Jan 23, and they matter to your portfolio because they shape market access, reimbursement prospects and long-term demand. Bipartisan bills that would put hemp and CBD under FDA oversight, plus talk of limited federal rescheduling focused on medical use, suggest regulatory clarity may be inching forward.
At the same time states kept delivering tangible revenue signals. Arkansas reported record medical cannabis sales for 2025, and Ohio started sending nearly $11 million in cannabis tax money to local governments. Those are the kind of metrics that can move earnings and valuation expectations once markets reopen on Monday, Jan 26.
Market Highlights
US markets are closed on Saturday, Jan 24. The last trading day was Friday, Jan 23. Keep that in mind when you check prices; the next session is Monday, Jan 26.
- Arkansas medical cannabis sales hit a record $291 million in 2025, topping the prior high of $283 million set in 2023 and representing a $15 million increase over 2024.
- Ohio has begun distributing cannabis-derived tax revenue to local governments, after officials had been withholding nearly $11 million in funds that were supposed to go to host communities.
- Federal policy attention is intensifying: President Trump’s Dec. 18 rescheduling order appears focused on medical cannabis, while two separate bipartisan efforts would put hemp and CBD under FDA rulemaking and create a path for CBD Medicare coverage.
- State reform momentum continued as Virginia lawmakers in both chambers advanced bills to legalize and regulate recreational marijuana sales under a pro-reform governor.
- Culture and consumer trends stayed visible, with brand-driven events like Jeeter Live and High Times features keeping public interest high.
- Stocks to watch in the sector include $MSOS, $TCNNF, $GTBIF, $CURLF, $TLRY. If you’re tracking these names, remember quoted closes will reflect Friday, Jan 23 levels until markets reopen on Monday.
Key Developments
Federal policy: rescheduling focus and new hemp/CBD bills
Analysis of President Trump’s Dec. 18 executive order suggests rescheduling language is aimed primarily at medical cannabis, not wholesale decriminalization. That distinction matters because it could limit immediate market access for adult-use firms, while still opening reimbursement and research pathways for medical operators.
Meanwhile, bipartisan bills filed on Jan 23 would assign FDA responsibility for regulating consumable hemp products and create a potential route for CBD coverage under Medicare. If these proposals gain traction, you could see a faster path to mainstream retail channels and insurance reimbursement for certain products.
State momentum and revenue flows
Arkansas’ $291 million in medical sales for 2025 is one of the clearest demand signals you’ll see this month. Strong state sales tend to support valuations for multistate operators that have exposure to smaller but steady medical markets.
Ohio’s release of almost $11 million in withheld cannabis tax revenue to local governments reduces a policy overhang that had created political uncertainty for operators and local hosts. That cash flow fix could ease municipal relations and speed permitting in some counties.
Psychedelics and political caution
Separately, bipartisan lawmakers warned that the psychedelics reform movement must avoid missteps to preserve momentum. That cautious note is a reminder that even friendly policy cycles carry execution risk, and that congressional strategy can make or break timetable expectations.
What to Watch
Policy will be the main driver next week. You should track the progress of the hemp enforcement and FDA jurisdiction bills and any congressional language that narrows or broadens federal rescheduling. Will rescheduling favor medical-only frameworks, or expand beyond that? That question matters for your allocations.
State-level calendars are active too. Virginia’s advance of legalization bills is a near-term catalyst for any operators with planned entry there. You should also watch for guidance and disbursement details from Ohio, which could affect local licensing timelines and retail openings.
From a market standpoint, pay attention to earnings and guidance from the big multistate operators and the sector ETFs. Watch $MSOS for ETF flows, and follow $TLRY, $CURLF, $GTBIF and $TCNNF for operational updates. If you’re holding these names, consider whether you want exposure to policy-driven upside or prefer to wait for clearer regulatory texts.
Bottom Line
- Policy momentum is bullish, with bipartisan bills and state reforms creating clearer paths for market expansion and reimbursement.
- Arkansas’ record $291 million in 2025 medical sales and Ohio’s release of nearly $11 million to local governments are concrete demand and cash-flow signals.
- Rescheduling language that may be limited to medical cannabis introduces nuance; investors should watch legislative language closely.
- Keep an eye on FDA rulemaking prospects and Medicare CBD coverage as potential catalysts that could move product distribution and pricing.
- Be selective: you can play upside via ETFs like $MSOS or targeted exposure to $TLRY, $CURLF, $GTBIF and $TCNNF depending on your risk tolerance.
FAQ Section
Q: Does rescheduling mean recreational marijuana will be legal nationwide? A: No, rescheduling that focuses on medical cannabis would not automatically legalize recreational use, it would mainly change federal scheduling for medical research and prescribing.
Q: How would FDA regulation of hemp affect CBD companies and Medicare coverage? A: FDA oversight could create product standards and safety rules that help legitimize CBD, and bipartisan proposals are seeking pathways to enable Medicare coverage, which could boost demand.
Q: Should I buy cannabis ETFs or individual operators ahead of policy moves? A: ETFs like $MSOS offer diversified exposure to policy-driven upside, while individual stocks can be higher reward and higher risk. Think about your time horizon and how much regulatory uncertainty you can tolerate.